• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Monogram Technologies Inc.

    8/14/24 5:13:14 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care
    Get the next $MGRM alert in real time by email
    NT 10-Q 1 tm2415236d2_nt10q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

    (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q  ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR  

     

    For Period Ended: June 30, 2024
     
    ¨ Transition Report on Form 10-K
    ¨ Transition Report on Form 20-F
    ¨ Transition Report on Form 11-K
    ¨ Transition Report on Form 10-Q
    ¨ Transition Report on Form N-SAR
     
    For the Transition Period Ended:______________________________________________________

     

     
    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
     

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

    PART I - REGISTRANT INFORMATION

    Monogram Technologies Inc.

    Full Name of Registrant

    Monogram Orthopaedics Inc.

    Monogram Arthroplasty Inc.

    Former Name if Applicable

    3919 Todd Lane

    Address of Principal Executive Office (Street and Number)

    Austin, TX 78744

    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Due to events unforeseen by the Company, it is unable to complete its Quarterly Report on Form 10-Q for the period ending June 30, 2024 without an unreasonable effort and expense. The Company expects to file its June 30, 2024 Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission within 5 calendar days of the prescribed due date.

     

    PART IV - OTHER INFORMATION

     

    (1)Name and telephone number of person to contact in regard to this notification

     

    Benjamin Sexson 512 399-2656
    (Name) (Area Code) (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes x No ¨

     

    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ¨ No x

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    Monogram Technologies Inc.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

      MONOGRAM TECHNOLOGIES INC.
         
    Date: August 14, 2024 By: /s/ Benjamin Sexson
        Name: Benjamin Sexson
        Title:   Chief Executive Officer

     

     

    Get the next $MGRM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRM

    DatePrice TargetRatingAnalyst
    12/9/2024$4.00Buy
    ROTH MKM
    More analyst ratings

    $MGRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Monogram Technologies with a new price target

    ROTH MKM initiated coverage of Monogram Technologies with a rating of Buy and set a new price target of $4.00

    12/9/24 7:59:36 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Announces World's First Fully Autonomous Saw-Based Robotic Knee Replacement Surgery

    The Procedure Utilized Monogram's mBôs TKA System Performed in India with Shalby Hospitals Groundbreaking Procedure Delivers the World's First Autonomous Saw-Based Robotic TKA Surgery on a Live Patient AUSTIN, Texas, July 29, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company revolutionizing orthopedic surgery, today announced that on Saturday, July 26, 2025, Monogram completed the first ever fully autonomous saw-based robotic knee replacement procedure on a live patient. The procedure was performed at the Krishna Shalby Hospital in Ahmedabad India, as part of Monogram's multi-center clin

    7/29/25 9:30:05 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

    USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 22, 2025 /PRNewswire/ -- USA News Group News Commentary – The AI revolution in healthcare is fully underway, with the potential to save lives and money, but there's still more to come. Healthcare startups are already figuring out how to implement AI to multiply their patients, and chase profits, to the benefit of investors. More Americans than ever are utilizing AI to diagnose their health issues, as the adoption of AI tools is becoming the norm among medical professionals. Now the developers of these game-changing technologies are overcoming regulatory barriers and moving closer to implementation o

    7/22/25 9:15:00 AM ET
    $AGEN
    $CLOV
    $MGRM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Medical/Dental Instruments

    $MGRM
    SEC Filings

    View All

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:11 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Monogram Technologies Inc.

    EFFECT - Monogram Technologies Inc. (0001769759) (Filer)

    11/20/25 12:15:14 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12G filed by Monogram Technologies Inc.

    15-12G - Monogram Technologies Inc. (0001769759) (Filer)

    10/21/25 11:59:09 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:59:13 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Gray Colleen

    4 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:58:09 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Gray Colleen

    3 - Monogram Technologies Inc. (0001769759) (Issuer)

    10/14/25 9:57:01 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Leadership Updates

    Live Leadership Updates

    View All

    Monogram Accepted to NVIDIA Inception Program

    Collaboration to Provide Monogram with Technical Resources to Drive Development and Commercialization of mBôs SystemAUSTIN, TX / ACCESSWIRE / April 11, 2024 / Monogram Orthopaedics Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), a medical technology company focused on reconstructive joint procedures and surgical robotics, today announced it has joined NVIDIA Inception, a program designed to help companies evolve faster through cutting-edge technology and access to the latest technical resources from NVIDIA.NVIDIA Inception will help drive Monogram to help drive development of its mBôs robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation co

    4/11/24 1:20:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    $MGRM
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Second Quarter 2025 Financial Results

    Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basisSecond quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0%Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted1 earnings per share financial guidance to $8.10 - $8.30WARSAW, Ind., Aug. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025.  T

    8/7/25 6:30:00 AM ET
    $MGRM
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties

    Monogram Technologies Reports First Quarter 2025 Financial Results

    Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World's First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the first quarter ended March 31, 2025. First Quarter 2025 and Subsequent Operational Highlights The U.S. Food and Drug Administration ("FDA") granted 510(k)

    5/14/25 4:01:00 PM ET
    $MGRM
    Medical/Dental Instruments
    Health Care

    Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

    AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones. A press release detailing these results will be issued prior to the call.Monogram CEO Ben Sexson and CFO Noel Knape will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can b

    11/12/24 8:31:00 AM ET
    $MGRM
    Medical/Dental Instruments
    Health Care